339 related articles for article (PubMed ID: 30597327)
41. Recent Development of Novel HDAC6 Isoform-selective Inhibitors.
Zhao Y; Liang T; Hou X; Fang H
Curr Med Chem; 2021; 28(21):4133-4151. PubMed ID: 33176627
[TBL] [Abstract][Full Text] [Related]
42. Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation.
Vergani B; Sandrone G; Marchini M; Ripamonti C; Cellupica E; Galbiati E; Caprini G; Pavich G; Porro G; Rocchio I; Lattanzio M; Pezzuto M; Skorupska M; Cordella P; Pagani P; Pozzi P; Pomarico R; Modena D; Leoni F; Perego R; Fossati G; Steinkühler C; Stevenazzi A
J Med Chem; 2019 Dec; 62(23):10711-10739. PubMed ID: 31710483
[TBL] [Abstract][Full Text] [Related]
43. HDAC6 inhibition protects cardiomyocytes against doxorubicin-induced acute damage by improving α-tubulin acetylation.
Song R; Yang Y; Lei H; Wang G; Huang Y; Xue W; Wang Y; Yao L; Zhu Y
J Mol Cell Cardiol; 2018 Nov; 124():58-69. PubMed ID: 30315806
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of cell migration and induction of apoptosis by a novel class II histone deacetylase inhibitor, MCC2344.
Dawood M; Fleischer E; Klinger A; Bringmann G; Shan L; Efferth T
Pharmacol Res; 2020 Oct; 160():105076. PubMed ID: 32659428
[TBL] [Abstract][Full Text] [Related]
45. A highly HDAC6-selective inhibitor acts as a fluorescent probe.
Ho YH; Wang KJ; Hung PY; Cheng YS; Liu JR; Fung ST; Liang PH; Chern JW; Yu CW
Org Biomol Chem; 2018 Oct; 16(42):7820-7832. PubMed ID: 30168823
[TBL] [Abstract][Full Text] [Related]
46. Fragment-Based Drug Design of Selective HDAC6 Inhibitors.
Ruzic D; Djokovic N; Nikolic K
Methods Mol Biol; 2021; 2266():155-170. PubMed ID: 33759126
[TBL] [Abstract][Full Text] [Related]
47. Development and therapeutic impact of HDAC6-selective inhibitors.
Dallavalle S; Pisano C; Zunino F
Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
[TBL] [Abstract][Full Text] [Related]
48. Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.
Lin X; Chen W; Qiu Z; Guo L; Zhu W; Li W; Wang Z; Zhang W; Zhang Z; Rong Y; Zhang M; Yu L; Zhong S; Zhao R; Wu X; Wong JC; Tang G
J Med Chem; 2015 Mar; 58(6):2809-20. PubMed ID: 25734520
[TBL] [Abstract][Full Text] [Related]
49. HDAC6 α-tubulin deacetylase: a potential therapeutic target in neurodegenerative diseases.
Li G; Jiang H; Chang M; Xie H; Hu L
J Neurol Sci; 2011 May; 304(1-2):1-8. PubMed ID: 21377170
[TBL] [Abstract][Full Text] [Related]
50. The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease.
Cosenza M; Pozzi S
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30096875
[TBL] [Abstract][Full Text] [Related]
51. Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: Rational design, synthesis and antiproliferative activity.
Chen X; Chen X; Steimbach RR; Wu T; Li H; Dan W; Shi P; Cao C; Li D; Miller AK; Qiu Z; Gao J; Zhu Y
Eur J Med Chem; 2020 Feb; 187():111950. PubMed ID: 31865013
[TBL] [Abstract][Full Text] [Related]
52. Histone deacetylase 6 in health and disease.
Seidel C; Schnekenburger M; Dicato M; Diederich M
Epigenomics; 2015; 7(1):103-18. PubMed ID: 25687470
[TBL] [Abstract][Full Text] [Related]
53. Synthesis of a selective HDAC6 inhibitor active in neuroblasts.
Zwick V; Simões-Pires CA; Nurisso A; Petit C; Dos Santos Passos C; Randazzo GM; Martinet N; Bertrand P; Cuendet M
Bioorg Med Chem Lett; 2016 Oct; 26(20):4955-4959. PubMed ID: 27650925
[TBL] [Abstract][Full Text] [Related]
54. Bicyclic-Capped Histone Deacetylase 6 Inhibitors with Improved Activity in a Model of Axonal Charcot-Marie-Tooth Disease.
Shen S; Benoy V; Bergman JA; Kalin JH; Frojuello M; Vistoli G; Haeck W; Van Den Bosch L; Kozikowski AP
ACS Chem Neurosci; 2016 Feb; 7(2):240-58. PubMed ID: 26599234
[TBL] [Abstract][Full Text] [Related]
55. Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
Yoo J; Kim SJ; Son D; Seo H; Baek SY; Maeng CY; Lee C; Kim IS; Jung YH; Lee SM; Park HJ
Eur J Med Chem; 2016 Jun; 116():126-135. PubMed ID: 27060764
[TBL] [Abstract][Full Text] [Related]
56. HDAC6: physiological function and its selective inhibitors for cancer treatment.
Yang PH; Zhang L; Zhang YJ; Zhang J; Xu WF
Drug Discov Ther; 2013 Dec; 7(6):233-42. PubMed ID: 24423654
[TBL] [Abstract][Full Text] [Related]
57. HDAC6 inhibition promotes α-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice.
Picci C; Wong VSC; Costa CJ; McKinnon MC; Goldberg DC; Swift M; Alam NM; Prusky GT; Shen S; Kozikowski AP; Willis DE; Langley B
Exp Neurol; 2020 Jun; 328():113281. PubMed ID: 32147437
[TBL] [Abstract][Full Text] [Related]
58. How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics.
Zhang Y; Ying JB; Hong JJ; Li FC; Fu TT; Yang FY; Zheng GX; Yao XJ; Lou Y; Qiu Y; Xue WW; Zhu F
ACS Chem Neurosci; 2019 May; 10(5):2467-2480. PubMed ID: 30784262
[TBL] [Abstract][Full Text] [Related]
59. Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
Yang Z; Wang T; Wang F; Niu T; Liu Z; Chen X; Long C; Tang M; Cao D; Wang X; Xiang W; Yi Y; Ma L; You J; Chen L
J Med Chem; 2016 Feb; 59(4):1455-70. PubMed ID: 26443078
[TBL] [Abstract][Full Text] [Related]
60. Fluorescence Polarization-Based Competition Assays to Evaluate Histone Deacetylase 6 Inhibitors.
Ashraf QF; Quilates EJ; Olaoye OO; de Araujo ED; Gunning PT
Methods Mol Biol; 2023; 2589():481-492. PubMed ID: 36255644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
